Latest Ratios: P/E Ratio 52.0x · EV/EBITDA 19.9x · ROE 8.4%. (2022–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Market Cap | $56M | $92M | $288M | — | — |
| Enterprise Value | $48M | $84M | $280M | — | — |
| P/E Ratio → | 52.00 | 79.50 | 435.77 | — | — |
| P/S Ratio | 1.68 | 2.75 | 14.76 | — | — |
| P/B Ratio | 3.51 | 5.37 | 21.84 | — | — |
| P/FCF | — | — | 225.51 | — | — |
| P/OCF | 17.86 | 29.30 | 132.17 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| EV / Revenue | — | 2.53 | 14.37 | — | — |
| EV / EBITDA | 19.95 | 34.70 | 182.87 | — | — |
| EV / EBIT | 31.70 | 50.34 | 202.30 | — | — |
| EV / FCF | — | — | 219.52 | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Gross Margin | 62.8% | 62.8% | 79.2% | 88.0% | 94.2% |
| Operating Margin | 4.6% | 4.6% | 5.1% | 17.7% | 3.6% |
| Net Profit Margin | 3.8% | 3.8% | 3.4% | 12.9% | 1.4% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| ROE | 8.4% | 8.4% | 7.0% | 65.9% | 5.6% |
| ROA | 6.6% | 6.6% | 4.9% | 12.4% | 0.3% |
| ROIC | 15.2% | 15.2% | 13.4% | 86.9% | 62.6% |
| ROCE | 9.7% | 9.7% | 9.7% | 60.1% | 4.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.02 | 0.31 | 0.22 |
| Debt / EBITDA | 0.06 | 0.06 | 0.14 | 0.51 | 1.54 |
| Net Debt / Equity | — | -0.44 | -0.58 | -0.08 | -0.83 |
| Net Debt / EBITDA | -3.10 | -3.10 | -4.99 | -0.13 | -5.70 |
| Debt / FCF | — | — | -5.99 | -1.30 | — |
| Interest Coverage | — | — | 2.80 | 1668.59 | 44.97 |
Net cash position: cash ($8M) exceeds total debt ($139812)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Current Ratio | 3.13 | 3.13 | 5.06 | 1.43 | 1.06 |
| Quick Ratio | 3.13 | 3.13 | 5.06 | 1.43 | 1.06 |
| Cash Ratio | 1.49 | 1.49 | 3.68 | 0.51 | 0.06 |
| Asset Turnover | — | 1.44 | 1.24 | 1.66 | 0.20 |
| Inventory Turnover | — | — | — | — | — |
| Days Sales Outstanding | — | 8.28 | 40.21 | 74.65 | 61.80 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Earnings Yield | 1.9% | 1.3% | 0.2% | — | — |
| FCF Yield | — | — | 0.4% | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $58M | $54M | $54M | $54M |
Margin compression from scaling
Based on current market data, HIT trades at a P/S multiple of 1.68 and an EV/EBITDA of 19.95, suggesting that investors are pricing in significant future growth despite the company's recent shift toward negative operating margins and the absence of a clear path to near-term profitability.
The valuation appears to reflect a high-growth SaaS premium, yet the underlying financial reality of a 4.59% operating margin suggests that the market may be overestimating the scalability of the current reference-based pricing model. Investors should monitor whether the company can justify these multiples through sustained margin expansion, as the current P/E of 52.00 implies a growth trajectory that may be difficult to maintain if provider resistance continues to escalate.
As reported in financial statements, ROIC has deteriorated from a peak of 19.5% in 2023Q4 to -15.4% in 2026Q1, indicating that the company's aggressive investment in market penetration is currently failing to generate returns that exceed the cost of capital required to sustain its operational footprint.
The sharp decline in ROIC suggests that the capital allocated toward scaling the eDIYBS platform is not yet yielding the expected efficiency gains, likely due to the high-touch nature of managing captive insurance networks. This trend warrants further investigation into whether the current capital allocation strategy is prioritizing growth at the expense of long-term value creation for shareholders.
According to historical data, asset turnover has remained stagnant near 0.34x, while the volatility in DSO, which reached 55 days in 2025Q2, suggests that the company is facing increasing friction in converting its service-based revenue into actual cash inflows from its small-to-medium business client base.
The inability to improve asset turnover despite rapid revenue growth implies that the business model remains inherently labor-intensive rather than purely software-driven. This inefficiency, combined with the lack of clear DPO trends, suggests that the company may be struggling to leverage its position with suppliers, potentially limiting its ability to optimize working capital during this aggressive scaling phase.
Based on the most recent quarterly filings, the current ratio of 3.13 provides a superficial sense of security, yet the absolute cash position of $7.6 million appears increasingly vulnerable given the company's negative free cash flow margin of 42.0% observed in the first quarter of 2026.
While the company maintains a clean balance sheet with minimal debt, the rapid depletion of cash reserves to fund operations suggests that the current liquidity position may be insufficient to support long-term growth without external financing. Investors should monitor the cash burn rate closely, as any further deterioration in liquidity could force management to seek dilutive capital raises to maintain its competitive position.
The market commonly misapplies standard SaaS P/S multiples to HIT, which obscures the reality that a significant portion of revenue is derived from high-touch, advocacy-heavy claims processing rather than purely automated software subscriptions, leading to an overestimation of the company's long-term operating leverage potential.
By treating HIT as a pure-play software firm, analysts likely overlook the structural costs associated with provider network management and the legal complexities of reference-based pricing. A more appropriate metric would be to adjust for the high cost of revenue and focus on the contribution margin per captive member, which would provide a more accurate assessment of the company's true earning power.
Includes 30+ ratios · 4 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying HIT stock.
Health In Tech, Inc.'s current P/E ratio is 52.0x. The historical average is 79.5x.
Health In Tech, Inc.'s current EV/EBITDA is 19.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 34.7x.
Health In Tech, Inc.'s return on equity (ROE) is 8.4%. The historical average is 21.7%.
Based on historical data, Health In Tech, Inc. is trading at a P/E of 52.0x. Compare with industry peers and growth rates for a complete picture.
Health In Tech, Inc. has 62.8% gross margin and 4.6% operating margin.
Health In Tech, Inc.'s Debt/EBITDA ratio is 0.1x, indicating low leverage. A ratio below 2x is generally considered financially healthy.